Variables in predicting survival based on treating "PSA-Only" relapse

Urologic Oncology: Seminars and Original Investigations

Volumn 21, Issue 4, 2003, Pages 292-304

  Moul, Judd W ^a,b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Hormonal therapy; Prostate cancer; PSA recurrence; Salvage therapy; Survival

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; BIOLOGICAL MARKER; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

BEAM THERAPY; BONE SCINTISCANNING; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CRYOTHERAPY; HUMAN; METASTASIS; ORCHIECTOMY; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; SALVAGE THERAPY; TREATMENT OUTCOME; BLOOD; BRACHYTHERAPY; DISEASE COURSE; MALE; MORTALITY; PREDICTION AND FORECASTING; PROSTATE; PROSTATE TUMOR; REVIEW; SCINTISCANNING; SURVIVAL RATE; TUMOR RECURRENCE;

BRACHYTHERAPY; DISEASE PROGRESSION; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 0142248845     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(03)00103-0     Document Type: Conference Paper

References (111)

1. Jemal A., Thomas A., Murray T., Thun M. Cancer statistics, 2003. CA Cancer J Clin. 53:2003;5-26
2. Stephenson R.A. Population-based prostate cancer trends in the PSA-era Data from the Surveillance, Epidemiology, and End Results (SEER) Program. Monogr Urol. 19:1998;1-19
3. Moul J.W., Wu H., Sun L., et al. Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen an overview of the Department of Defense Center for Prostate Disease Research national database. Surgery. 132:2002;213-219
4. Moul J.W. Treatment options for prostate cancer. Part I-stage, grade, PSA, and changes in the 1990. Am J Manag Care. 4:1998;1031-1036
5. Moul J.W. Prostate specific antigen only progression of prostate cancer. J Urol. 163:2000;1632-1642
6. Schulman C.C., Altwein J.E., Zlotta A.R. Treatment options after failure of local curative treatments in prostate cancer a controversial issue. BJU Int. 86:2000;1014-1022
7. Moul J.W. Prostate biopsy quantitative histology as a staging and prognostic factor. J Urol. 167:(2 Pt 1):2002;526-557
8. Ross P.L., Scardino P.T., Kattan M.W. A catalogue of prostate cancer nomograms. J Urol. 165:2001;1562-1568
9. Moul J.W., Connelly R.R., Lubeck D.P., et al. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. J Urol. 166:2001;1322-1327
10. Ravery V. The significance of recurrent PSA after radical prostatectomy benign versus malignant sources. Semin Urol Oncol. 17:1999;127
11. Poun C.R., Partin A.W., Epstein J.I., Walsh P.C. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am. 24:1997;395
12. Partin A.W., Pearson J.D., Landis P.K., et al. Evaluation of serum prostate specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastasis. Urology. 43:1994;649
13. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 281:1999;1591
14. Polascik T.J., Oesterling J.E., Partin A.W. Prostate specific antigen a decade of discovery - what we have learned and where we are going. J Urol. 162:1999;293
15. Amling C.L., Bergstralh E.J., Blute M.L., Slezak J.M. Defining prostate specific antigen progression after radical prostatectomy what is the most appropriate cut point? J Urol. 165:2001;1146
16. Freedland S.J., Sutter M.E., et al. Defining the ideal cut point for determining PSA recurrence after radical prostatectomy. Urology. 61:2003;365-369
17. Witherspoon L.R., Lapeyrolerie T. Sensitive prostate specific antigen measurements identify men with long disease free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy. J Urol. 157:1997;1322
18. Haese A., Huland E., Graefen M., Hammerer P. Ultrasensitive detection of prostate specific antigen in the follow-up of 422 patients after radical prostatectomy. J Urol. 161:1999;1206
19. Mostofi F.K., Sesterhenn I.A., Davis C.J., et al. Benign prostatic glands in the surgical margin in radical retropubic prostatectomies. J Urol. 159:(suppl. 5):1998;297. (#1147A)
20. Anagnostou T.G., Remzi M., Alavi S., et al. Biochemical failure due to residual benign prostate tissue after radical prostatectomy. Is there a need for an anastomotic biopsy after all? J Urol. 169:(suppl. 4):2003;440. (#1647A)
21. Cox J.D., Gallagher M.J., Hammond E.H., et al. Consensus statements on radiation therapy of prostate cancer guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel J Clin Urol. 17:1999;1155
22. Consensus statement guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 37:1997;1035. American Society for Therapeutic Radiology and Oncology Consensus Panel
23. Horwitz E.M., Uzzo R.G., Hanlon A.L., et al. Modifying the American society for therapeutic radiology and oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy alone. J Urol. 169:2003;2153-2159
24. Jhaveri F.M., Zippe C.D., Klein E.A., Kupelian P.A. Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer 10-year results. Urology. 54:1999;884
25. D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen M. Surrogate marker for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Natl Cancer Institute (in press)
26. Scher H.I. Management of prostate cancer after prostatectomy Treating the patient, not the PSA. JAMA. 281:1999;1642
27. Patel A., Dorey F., Franklin J., DeKernion J.B. Recurrence patterns after radical retropubic prostatectomy clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J U Urol. 158:1997;1441
28. D'Amico A.V., Cote K., Loffredo M., et al. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clinc Oncol. 20:2002;4567
29. Partin A.W., Pound C.R., Rootselaar C.V., Epstein J.E., Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy update. J Urol. 169:(suppl. 4):2003;241. (#935A)
30. Cher M.L., Bianco F.J., Lam J.S., et al. Limited role of radionuclide bone scintigraphy in patients with prostate antigen elevations after radical prostatectomy. J Urol. 160:1998;1387
31. Oh J., Colberg J.W., Ornstein D.K., et al. Current follow-up strategies after radical prostatectomy A survey of American Urological Association urologists. J Urol. 161:1999;520
32. Kane C.J., Amling C.L., Johnstone P.A., et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology. 61:2003;607-611
33. Kahn D., Williams R.D., Seldin D.W., Libertino J.A. Radioimmunoscintigraphy with 111 indium labeled CYT-356 for the detection of occult prostate cancer recurrence. J Urol. 152:1994;1490
34. Raj G.V., Partin A.W., Polascik T.J. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer. 94:2002;987
35. Kahn D., Williams R.D., Haseman M.K., Reed N.L. Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Urol. 16:1998;284
36. Hinkle G.H., Burgers J.K., Neal C.E., Texter J.H. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer. 83:1998;739
37. Elgamal A.A., Troychak M.J., Murphy G.P. Prostascint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy analysis of 136 scans of 100 patients. Prostate. 37:1998;261
38. Quintana J.C., Blend M.J. The dual-isotope Prostascint imaging procedure clinical experience and staging results in 145 patients. Clin Nucl Med. 25:2000;33
39. Welsh J.S., Yanez M.H., Chin B.B., Howard S.P. Indium-111 capromab pendetide (ProstaScint) images before and after salvage radiation therapy. Clin Nucl Med. 24:1999;983
40. Petronis J.D., Regan F., Lin K. Indium-111 capromab pendetide (Prostascint) imaging to detect recurrent and metastic prostate cancer. Clin Nucl Med. 23:1998;672
41. Kahn D., Williams R.D., Manyak M.J., et al. 111 Indium capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. J Urol. 159:1998;2041
42. Mohideen N., Flanigan R.J., Dillehay G., et al. Role of ProstaScint scan in the assessment of patients who undergo radiotherapy for biochemical failure after radical prostatectomy for prostate cancer. J Urol. 167:(4 (suppl.)):2002;174. (abstract).
43. Thomas C.T., Bradshaw P.T., Pollock B.H., et al. Indium-III-Capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol. 21:2003;1715-1721
44. Sodee D.B., Malguria N., Faulhaber P., Resnick M.I. Multicenter Prostascint imaging findings in 2154 patients with prostate cancer. The Prostascint Imaging Centers. Urology. 56:2000;988
45. Fang D.X., Stock R.G., Stone N.N., Krynyckyi B.R. Use of radioimmunoscintigraphy with indium-111-labeled CYT-356 (Prostascint) scan for evaluation of patients for salvage brachytherapy. Tech Urol. 6:2000;146
46. Foster L.S., Jajodia P., Fournier G.S., et al. The value of prostate-specific antigen and transrectal ultrasound guided biopsy in detecting prostatic fossa recurrences following radical prostatectomy. J Urol. 149:1993;1024
47. Shekarriz B., Upadhyay J., Wood D.P. Jr, et al. Vesicourethral anastomosis biopsy after radical prostatectomy predictive value of prostate-specific antigen and pathologic stage. Urology. 54:1999;1044
48. Kabalin J.N., Hodge K.K., McNeal J.E., et al. Identification of residual cancer in the prostate following radiation therapy role of transrectal ultrasound guided biopsy and prostate specific antigen. J Urol. 142:1989;326
49. Silverman J.M., Krebs T.L. MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy. AJR Am J Roentgenol. 168:1997;379
50. DeGrado T.R., Coleman R.E., Wang S., Baldwin S.W. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography initial findings in prostate cancer. Cancer Res. 61:2001;110
51. Forman J.D., Velasco J. Therapeutic radiation in patients with a rising post-prostatectomy PSA level. Oncology (Huntingt). 12:1998;33
52. Hudson M.A., Catalona W.J. Effect of adjuvant radiation therapy on prostate specific antigen following radical prostatectomy. J Urol. 143:1990;1174
53. Link P., Freiha F.S., Stamey T.A. Adjuvant radiation therapy in patients with detectable prostate specific antigen following radical prostatectomy. J Urol. 145:1991;532
54. Kaplan I.D., Bagshaw M.A. Serum prostate-specific antigen after post-prostatectomy radiotherapy. Urology. 39:1992;401
55. McCarthy J.F., Catalona W.J., Hudson M.A. Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy Early vs. delayed treatment. J Urol. 151:1994;1575
56. Wu J.J., King S.C., Montana G.S., McKinstry C.A. The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen. Int J Radiat Oncol Biol Phys. 32:1995;317
57. Haab F., Meulemans A., Boccon-Gibod L., Dauge M.C. Effect of radiation therapy after radical prostatectomy on serum prostate-specific antigen measured by an ultrasensitive assay. Urology. 45:1995;1022
58. Schild S.E., Buskirk S.J., Wong W.W., Halyard M.Y. The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. J Urol. 156:1996;1725
59. Medini E., Medini I., Reddy P.K., Levitt S.H. Delayed/salvage radiation therapy in patients with elevated prostate specific antigen levels after radical prostatectomy. A long-term follow-up. Cancer. 78:1996;1254
60. Coetzee L.J., Hars V., Paulson D.F. Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy. Urology. 47:1996;232
61. Forman J.D., Meetze K., Pontes E., Wood D.P. Jr. Therapeutic irradiation for patients with an elevated post-prostatectomy prostate specific antigen level. J Urol. 158:1997;1436
62. Morris M.M., Dallow K.C., Zeitman A.L., et al. Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys. 38:1997;731
63. Cadeddu J.A., Partin A.W., DeWeese T.L., Walsh P.C. Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol. 159:1998;173
64. Garg M.K., Tekyi-Mensah S., Bolton S., Velasco J. Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy. Urology. 51:1998;998
65. Raymond J.F., Vuong M., Russell K.J. Neutron beam radiotherapy for recurrent prostate cancer following radical prostatectomy. Int J Radiat Oncol Biol Phys. 41:1998;93
66. Valicenti R.K., Gomella L.G., Ismail M., Mullholland S.G. Pathologic seminal vesicle invasion after radical prostatectomy for patients with prostate carcinoma effect of early adjuvant radiation therapy on biochemical control. Cancer. 82:1998;1909
67. Egawa S., Matsumoto K., Suyama K., Soh S. Limited suppression of prostate-specific antigen after salvage radiotherapy for its isolated elevation after radical prostatectomy. Urology. 53:1999;148
68. Vicini F.A., Ziaja E.L., Kestin L.L., Brabbins D.S. Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer. Urology. 54:1999;111
69. Moul J.W., Paulson D.F. The role of radical surgery in the management of radiation recurrent and large volume prostate cancer. Cancer. 68:1991;1265
70. Garzotto M., Wajsman Z. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer results at 5-year followup. J Urol. 159:1998;950
71. Gheiler E.L., Tefilli M.V., Tiguert R., Grignon D. Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer. Urology. 51:1998;789
72. Chin J.L., Pautler S.E., Mouraviev V., et al. Results of salvage cryoablation of the prostate after radiation identifying predictors of treatment failure and complications. J Urol. 165:2001;1937
73. Grado G.L., Collins J.M., Kriegshauser J.S., et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology. 53:1999;2
74. Moul J.W. A better definition of advanced prostate cancer for today's patients. Contemp Urol. 1997;15-31
75. Cox L.E., Crawford E.D. Estrogens in the treatment of prostate cancer. J Urol. 154:1995;1991-1998
76. Labrie F., Dupont A., Belanger A., et al. Combination therapy with flutamide and castration (LH-RH agonist or orchiectomy) in advanced prostate cancer a marked improvement in survival. J Steroid Biochem Mol Biol. 23:1985;833-841
77. Eisenberger M.A., Blumenstein B.A., Crawford E.D., et al. Bilateral orchiectomy with or without flutamide for metastic prostate cancer. N Engl J Med. 339:1998;1036-1042
78. Bertagna C., DeGery A., Huchner M., Francois J.P., Zanirato J. Efficacy of the combination of nilutamide plus orchiectomy in patients with metastic prostate cancer a meta-analysis of seven randomized, double-blind trials (1056 patients). Br J Urol. 73:1994;396-402
79. Caubet J., Tosteson T.D., Dong E.W., et al. Maximum androgen blockade in advanced prostate cancer a meta-analysis of published randomized trials using nonsteroidal antiandrogen. Urology. 49:1997;71-78
80. Bennett C.L., Tosteson T.D., Schmitt B., Weinberg P.D., Ernstoff M.S., Ross S.D. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide. Prost Cancer Prost Dis. 2:1999;4-8
81. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer an overview of the randomized trials. Lancet. 355:2000;1491-1498
82. Crawford D.A., Eisenberger M.A., McLeod D.G., et al. A controlled trial of leuprolide with and without flutamide in prostate cancer. N Engl J Med. 321:1989;848-853
83. Klotz L. Combined androgen blockade in prostate cancer meta-analyses and associated issues. BJU Int. 87:2001;806-813
84. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial. Br J Urol 19)7;79:235-46
85. Kirk D. Immediate vs. delayed hormone treatment for prostate cancer how safe is androgen deprivation? BJU In. 86:(Suppl 3t):2000;220. (Abstr MP6.1.07)
86. Messing E., Manola J., Wilding G., Sarosdy M., Crawford D., Trump D. Immediate hormonal therapy vs. observation for node positive prostate cancer following radical prostatectomy and pelvic lymphadenectomy A randomized Phase III Eastern Cooperative Oncology Group trial. N Engl J Med. 341:1999;1781-1788
87. The Department of Defense Center for Prostate Disease Research (CPDR).. Anon Oncology (Huntingt). 13:1999;1336
88. Moul JW. Update of clinical and basic science research on prostate cancer from the Department of Defense Center for Prostate Disease Research (CPDR). Prost Cancer Prostatic Dis. 199;2(53):522
89. Moul J., McLeod DG., Amling CL., et al. Assessment of biochemical disease free survival (DFS) in patients with hormonal therapy (HT) started for PSA-only recurrence following radical prostatectomy. J Urol. 167:(suppl.):2002;. Abstr 699
90. Moul J., McLeod D.G., Amling C.L., Lance R., Kusuda L., Donahue T., Foley J., Chung A., Sexton W., Soderdahl D. Effect of Early Hormonal Therapy on Disease Free Survival (DFS) in Patients with PSA-only recurrence Following Radical Prostatectomy. Department of Defense Center for Prostate Disease Research (CPDR). Proceedings AACR. 44:2003;1237. (#5399)
91. Carter H.B., Epstein J.I., Chan D.W., Fozard J.L. Pearson JD. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA. 2779:(18):1997;1456-1460
92. Schröder F.H. Endocrine treatment of prostate cancer-recent developments and the future. Part I: Maximal androgen blockade, early vs. delayed endocrine treatment and side effects. BJU Int. 83:1999;161-170
93. Andriole G., Lieber M., Smith J., et al. Treatment with finasteride following radical prostatectomy for prostate cancer. Urology. 45:1995;491-497
94. Fleshner N.E., Trachtenberg J. Combination finasteride and flutamide in advanced carcinoma of the prostate Effective therapy with minimal side effects. J Urol. 154:1995;1642-1646
95. Fleshner N.E., Fair W.R. Anti-androgenic effects of combination finasteride plus flutamide in patients with prostatic carcinoma. Br J Urol. 78:1996;907-910
96. Ornstein D.K., Ganesh R.S., Johnson B., Charlton E.T., Andriole G.L. Combined finasteride and flutamide therapy in men with advanced prostate cancer. Urology. 48:1996;901-905
97. Brufsky A., Fontaine-Rothe P., Berlane K., et al. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology. 49:1997;913-920
98. Sandhu S.S., Matveev V.B., Kaisary A.V. Finasteride plus flutamide for prostatic carcinoma. Br J Urol. 80:1997;360
99. Moul J.W., Harding P., Crawford E.D., McLeod D.G. Combination flutamide and finasteride in PSA-only recurrence after prior local prostate cancer therapy. J Urol. 159:(suppl):1998;130. (Abstr 491)
100. Brooks J.R., Berman C., Nguyen H., et al. Effect of castration, DES, flutamide, and the 5 alpha-reductase inhibitor, MK-906, on growth of the Dunning rat prostatic carcinoma, R-3327. Prostate. 18:1991;215-217
101. Tsukamoto S., Akaza H., Onozawa M., Shirai T., Ideyama Y. Five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic carcinoma to macroscopic carcinoma in rats. Cancer. 82:1998;531-537
102. Verhelst J., Denis L., Van Vliet P., et al. Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer. Clin Endocrinol (Oxf). 41:1994;525-530
103. Bales G.T., Chodak G.W. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology. 47:1996;38-43
104. Iversen P., Tyrrell C.J., Kaisary A.V., et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer. 6.3 years of follow-up. J Urol. 164:2000;1579-1582
105. Tyrrell C.J., Kaisary A.V., Iversen P., et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol. 33:1998;447-456
106. Kaisary A.V., Iversen P., Tyrrell C.J., Carroll K., Morris T. Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer? Prost Cancer Prost Dis. 4:2001;196-203
107. Boccardo F., Rubagotti A., Barichello M., et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients Results of an Italian Prostate Cancer Project study. J Clin Oncol. 17:1999;2027-2038
108. Fourcade R.O., Chatelain C., Poterre M. An open multicenter randomised study to compare the effect and safety of Casodex (bicalutamide) 150 mg monotherapy with castration plus nilutamide in metastatic prostate cancer. Eur Urol. 33:(suppl 1.):1998;88. (Abstr 349)
109. See W.A., Wirth M.P., McLeod D.G., et al. Bicalutamide ('Casodex') 150 mg as immediate therapy either alone or as adjuvant to standard care in patients with localized or locally advanced prostate cancer first analysis of the early prostate cancer program. J Urol. 168:2002;429-435
110. Schröder F.H. Antiandrogens as monotherapy for prostate cancer. Eur Urol. 34:(suppl 3):1998;12-17
111. Lisle T., Mackenzie S., Ziada A., et al. Androgen deprivation therapy using finasteride and low dose flutamide to treat PSA failure following therapy for clinically localized adenocarcinoma of the prostate (CaP). J Urol. 161:(suppl 4.):1999;299. (Abstr 1151)